Current status of liver transplantation for hepatocellular carcinoma from living donors

Authors

  • Masatoshi Makuuchi,

    1. Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Search for more papers by this author
  • Yasuhiko Sugawara

    1. Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Search for more papers by this author

Yasuhiko Sugawara, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Email: yasusugatky@yahoo.co.jp

Abstract

The first successful living-donor liver transplantation (LDLT) was performed in a child in 1989 in Brisbane, Australia and in an adult in 1994 by the Shinshu group. Over the past few years, LDLT has increased worldwide and is now an established alternative to deceased-donor liver transplantation. Hepatocellular carcinoma is one of the major indications for LDLT. At present, however, there are no universally adoptedselection criteria in potential candidates for LDLT. In our institution, patients were selected based on a tumor number of five or fewer and a maximum diameter of less than 5 cm with 3-year survival of 82%.

Ancillary